Galleri multi-cancer early detection test is available now at our office.
Your health is our top priority at Memorial Dermatology, so we want you to know about the Galleri test. Galleri® is a multi-cancer early detection test — a blood test that can screen for many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today. 1,2,3 This is all possible through a single blood test. The Galleri test can be taken annually. Deadly cancers can develop at any time and progress quickly, sometimes in less than a year. Adding the Galleri test to recommended single-cancer screenings may help detect more cancers at an early stage (based on modeled data). 4,5 Are you interested in taking the next step? At your next visit, ask your healthcare provider about the Galleri test.
Call us today at 713-468-2200 to schedule a consultation with one of our providers. We’ll be happy to help!
Rx only. Review Important Safety Information by visiting Galleri.com/safety
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Important Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
© 2025 GRAIL, INC. ALL RIGHTS RESERVED. GALLERI IS A REGISTERED TRADEMARK OF GRAIL, INC. US-GA-
2400488-2 (US-GA-2500100-3)
Laboratory / Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
References
1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. doi:10.1016/j.annonc.2021.05.806
2.US Preventive Services Task Force. A,B,C grade recommendations, cancer, and screenings. [cited 2023 Oct 23]. https://www.uspreventiveservic...
3. American Cancer Society. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, LLC. Data on file: GA-2021-0065]
4. Patel A. Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer;Prevention Study-3 (CPS-3) cohort. American Society of Clinical Oncology (ASCO) Annual Meeting; 2023 Jun2-6. https://meetings.asco.org/abst...
5. Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. European Society for Medical Oncology (ESMO) Virtual Congress [poster]; 2021 Sep 16-21.